替比夫定片联合扶正化瘀胶囊治疗慢性乙肝肝纤维化临床观察

The clinical observation of Sebivo combined Fuzhenghuayu capsule treatment of chronic hepatitis B with liver fibrosis

目的观察替比夫定片联合扶正化瘀胶囊慢性乙型病毒性肝炎肝纤维化指标的影响.方法：将94 例慢性乙肝患者随机分为两组,治疗组46 例患者口服替比夫定片、扶正化瘀胶囊;对照组46 例接受口服替比夫定片.两组疗程均为48 周.结果：联合治疗组患者48 周后肝纤维化指标下降幅度明显高于对照组（P〈0.05）;联合治疗组48 周时脾脏厚度恢复正常.门静脉内径明显缩小.与治疗前比较,差异均有显著性意义（P〈0.05）;其中48 周时联合治疗组与单药治疗组比较,差异有显著性意义（P〈O.05）.结论：替比夫定片联合扶正化瘀胶囊治疗慢性乙肝抗肝纤维化疗效优于替比夫定片单药治疗.

objective:To explore the effect of Fuzhenghuayu capsule combined Sebivo on liver fibrosis in chronic hepatitis B.Methods:94 patients with chronic hepatitis B patients were randomly divided into combined treatment group(n=46,Sebivo combined Fuzhenghuayu capsule)and the control group(n=46,Sebivo alone).Clinical efficacy was observed 48 weeks later.Results:After 48 weeks,1iver fibrosis indexs in the treatment group was significantly lower than control group(P<0.05).Before treatment,spleen returned to normal thickness,portal vein diameter significantly reduced in treatment group,the differences were significant(P<0.05).Conclusion:Fuzhenghuayu capsule combined Sebivo was effective on liver fibrosis in chronic hepatitis B.